Skip to main content

Advertisement

SpringerLink
Log in

Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: Ten years of successful antivascular therapy

  • Invited Commentary
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Conclusions

TNF-based ILP is very successful as a treatment to achieve limb salvage in the management of advanced, multiple, or drug-resistant extremity tumors. TNF-based ILP is now performed in 30 cancer centers in Europe. TNF-based antivascular therapy for cancer is here to stay, and its potential needs to be studied further [7].

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lienard D, Ewalenko P, Delmotte JJ, et al.: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992, 10:50–62.

    Google Scholar 

  2. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al.: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg 1996, 224:756–765.

    Article  PubMed  CAS  Google Scholar 

  3. De Wilt JHW, ten Hagen TLM, de Boeck G, et al.: Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000, 82:1000–1003.

    Article  PubMed  Google Scholar 

  4. Ruegg C, Yilmaz A, Bieler G, et al.: Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFNgamma. Nat Med 1998, 4:408–414.

    Article  PubMed  CAS  Google Scholar 

  5. Alexander HR Jr, Bartlett DL, Libutti SK, et al.: Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998, 16:1479–1489.

    PubMed  CAS  Google Scholar 

  6. Ten Hagen TL, Van Der Veen AH, Nooijen PT, et al.: Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 2000, 87:829–837.

    Article  PubMed  Google Scholar 

  7. Ten Hagen TLM, Lejeune FJ, Eggermont AMM: TNF is here to stay—revisited. Trends Immunol 2001, 22:127–129.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075, Rotterdam, EA, Netherlands

    Alexander M. M. Eggermont MD, PhD & Timo L. M. ten Hagen PhD

Authors
  1. Alexander M. M. Eggermont MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timo L. M. ten Hagen PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eggermont, A.M.M., Hagen, T.L.M.t. Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: Ten years of successful antivascular therapy. Curr Oncol Rep 5, 79–80 (2003). https://doi.org/10.1007/s11912-003-0091-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-003-0091-x

Keywords

Search

Navigation